| Literature DB >> 23153245 |
Shuilian Chen1, Feng Jiang, Jiangping Ren, Jiajing Liu, Wei Meng.
Abstract
BACKGROUND: Interleukin (IL)-18, an important proinflammatory cytokine, plays a potential pathological role in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Studies on the relationship of IL-18 gene promoter rs1946518 (-607A/C) polymorphism, rs187238 (-137G/C) polymorphism with RA and SLE are inconclusive. The aim of this study was to get a more precise estimation of the relationship in Asian populations.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23153245 PMCID: PMC3523015 DOI: 10.1186/1471-2350-13-107
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Figure 1Flow diagram summarizing the search strategy for meta-analysis of IL-18 gene and RA and SLE.
Characteristics of studies included in a meta-analysis of the IL-18 polymorphisms and rheumatoid arthritis and systemic lupus erythematosus
| RA | Sivalingam SP.2003 [ | Singapore | Chinese | 309(74/235) | rs1946518 | PCR-SSP | <0.001 |
| RA | Sivalingam SP.2003 [ | Singapore | Chinese | 309(74/235) | rs187238 | PCR-SSP | 0.442 |
| RA | Sivalingam SP.2003 [ | Singapore | Indian | 45(23/22) | rs1946518 | PCR-SSP | 0.079 |
| RA | Sivalingam SP.2003 [ | Singapore | Indian | 45(23/22) | rs187238 | PCR-SSP | 0.548 |
| RA | Sivalingam SP.2003 [ | Singapore | Malay | 25(9/16) | rs1946518 | PCR-SSP | 0.605 |
| RA | Sivalingam SP.2003 [ | Singapore | Malay | 25(9/16) | rs187238 | PCR-SSP | 0.904 |
| RA | Huang XZ.2007 [ | China | Chinese | 287(119/168) | rs1946518 | PCR-SSP | 0.783 |
| RA | Huang XZ.2007 [ | China | Chinese | 288(120/168) | rs187238 | PCR-SSP | 0.728 |
| RA | Sugiura T.2011 [ | Japan | Japanese | 2432(1462/970) | rs1946518 | TaqMan | 0.052 |
| RA | Ying B.2011 [ | China | Chinese | 360(164/196) | rs1946518 | PCR–RFLP | 0.543 |
| RA | Shi P.2011 [ | China | Chinese | 207(107/100) | rs1946518 | PCR-SSP | 0.115 |
| RA | Shi P.2011 [ | China | Chinese | 207(107/100) | rs187238 | PCR-SSP | 0.677 |
| SLE | Xu Q.2007 [ | Singapore | Chinese | 231(113/118) | rs1946518 | PCR–RFLP | 0.050 |
| SLE | Xu Q.2007 [ | Singapore | Chinese | 231(113/118) | rs187238 | PCR-SSP | 0.334 |
| SLE | Lin YJ.2007 [ | China(Taiwan) | Chinese | 301(160/141) | rs1946518 | Probe hybridization | 0.088 |
| SLE | Lin YJ.2007 [ | China(Taiwan) | Chinese | 307(161/146) | rs187238 | Probe hybridization | 0.290 |
| SLE | Lan Y.2008 [ | China | Chinese | 275(115/160) | rs1946518 | PCR–RFLP | 0.606 |
| SLE | Lan Y.2008 [ | China | Chinese | 275(115/160) | rs187238 | PCR–RFLP | 0.727 |
| SLE | Chen DY.2009 [ | China(Taiwan) | Chinese | 339(165/174) | rs1946518 | PCR–RFLP | 0.130 |
| SLE | Hirankarn N.2009 [ | Thailand | Thai | 258(116/142) | rs1946518 | PCR-SSP | 0.061 |
| SLE | Hirankarn N.2009 [ | Thailand | Thai | 258(116/142) | rs187238 | PCR-SSP | 0.868 |
| SLE | Ye ZZ.2009 [ | China | Chinese | 289(165/124) | rs1946518 | PCR-SSP | 0.549 |
| SLE | Ye ZZ.2009 [ | China | Chinese | 289(165/124) | rs187238 | PCR-SSP | 0.030 |
Meta-analysis of the IL-18 gene polymorphisms and RA risk
| rs1946518 | | | | | | | | |
| Additive | 7 | 0.752 | 0.562-1.006 | 0.055 | R | 77.80% | <0.001 | 0.065 |
| Dominant | 7 | 0.730 | 0.479-1.113 | 0.144 | R | 74.40% | 0.001 | 0.067 |
| Recessive | 7 | 0.537 | 0.271-1.064 | 0.075 | R | 76.20% | <0.001 | 0.290 |
| rs187238 | | | | | | | | |
| Additive | 5 | 1.316 | 0.828-2.092 | 0.246 | R | 48.90% | 0.098 | 0.845 |
| Dominant | 4 | 1.196 | 0.466-3.073 | 0.710 | F | 45.80% | 0.136 | 0.445 |
| Recessive | 5 | 1.347 | 0.963-1.885 | 0.082 | F | 22.40% | 0.272 | 0.657 |
R: random model F: fixed model.
Studies of the rs1946518 and rs187238 polymorphisms in IL-18 gene and risk of RA and SLE under additive model grouped by study characteristics
| 7 | 77.80% | 0.752(0.562-1.006) | 0.055 | 6 | 88.10% | 0.684(0.455-1.028) | 0.068 | |
| Population | | | | | | | | |
| Chinese | 4 | 52.90% | 0.688(0.532-0.889) | 0.004 | 5 | 87.00% | 0.606(0.396-0.930) | 0.022 |
| Other | 3 | 40.10% | 1.074(0.958-1.205) | 0.702 | 1 | NA | 1.250(0.883-1.771) | 0.208 |
| Genotyping method | | | | | | | | |
| PCR-SSP | 5 | 36.50% | 0.636(0.519-0.781) | <0.001 | 2 | 96.70% | 0.596(0.139-2.560) | 0.487 |
| PCR–RFLP | 1 | NA | 0.817(0.604-1.105) | 0.189 | 3 | 74.60% | 0.670(0.454-0.989) | 0.044 |
| other | 1 | NA | 1.088(0.969-1.222) | 0.155 | 1 | NA | 0.945(0.686-1.303) | 0.731 |
| Sample size | | | | | | | | |
| ≥300 | 3 | 50.60% | 0.959(0.781-1.178) | 0.693 | 3 | 76.80% | 0.773(0.519-1.152) | 0.207 |
| <300 | 4 | 0.00% | 0.559(0.438-0.715) | <0.001 | 3 | 93.50% | 0.605(0.267-1.369) | 0.228 |
| HWE status | | | | | | | | |
| Meeting HWE | 6 | 81.30% | 0.727(0.513-1.031) | 0.073 | 6 | 88.10% | 0.684(0.455-1.028) | 0.068 |
| Deviating HWE | 1 | NA | 0.857(0.590-1.244) | 0.416 | 0 | NA | NA | NA |
| 5 | 48.90% | 1.296(0.959-1.751) | 0.246 | 5 | 33.70% | 1.166(0.948-1.435) | 0.145 | |
| Population | | | | | | | | |
| Chinese | 3 | 70.30% | 1.262(0.703-2.264) | 0.436 | 4 | 45.60% | 1.209(0.961-1.520) | 0.105 |
| Other | 2 | 0.00% | 1.628(0.631-4.199) | 0.314 | 1 | NA | 0.996(0.614-1.616) | 0.986 |
| Genotyping method | | | | | | | | |
| PCR-SSP | 5 | 48.90% | 1.296(0.959-1.751) | 0.246 | 3 | 0.00% | 1.300(0.991-1.705) | 0.416 |
| Other | 0 | NA | NA | NA | 2 | 65.10% | 0.987(0.570-1.710) | 0.963 |
| Sample size | | | | | | | | |
| ≥150 | 3 | 70.30% | 1.262(0.703-2.264) | 0.436 | 2 | 0.00% | 1.351(0.990-1.845) | 0.058 |
| <150 | 2 | 0.00% | 1.628(0.631-4.199) | 0.314 | 3 | 54.70% | 1.040(0.686-1.577) | 0.854 |
| HWE status | | | | | | | | |
| Meeting HWE | 5 | 48.90% | 1.296(0.959-1.751) | 0.246 | 4 | 34.20% | 1.095(0.870-1.377) | 0.439 |
| Deviating HWE | 0 | NA | NA | NA | 1 | NA | 1.537(0.942-2.508) | 0.085 |
a: p value of Z test NA: not available.
Meta-analysis of the IL-18 gene polymorphisms and SLE risk
| rs1946518 | | | | | | | | |
| Additive | 6 | 0.684 | 0.455-1.028 | 0.068 | R | 88.10% | <0.001 | 0.118 |
| Dominant | 6 | 0.645 | 0.368-1.130 | 0.125 | R | 86.00% | <0.001 | 0.236 |
| Recessive | 6 | 0.672 | 0.447-1.010 | 0.056 | R | 61.20% | 0.024 | 0.275 |
| rs187238 | | | | | | | | |
| Additive | 5 | 1.166 | 0.948-1.435 | 0.145 | F | 33.70% | 0.197 | 0.412 |
| Dominant | 5 | 1.185 | 0.911-1.543 | 0.206 | F | 0.00% | 0.961 | 0.401 |
| Recessive | 5 | 1.688 | 0.553-5.153 | 0.358 | R | 76.40% | 0.002 | 0.561 |